CAR vs LIMN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CAR and LIMN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CAR and LIMN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Avis Budget Group runs one of the three big global vehicle-rental platforms, operating the Avis, Budget, Budget Truck, Payless and Zipcar brands across airport, off-airport, urban and international markets. Revenue comes from renting a large owned-and-leased vehicle fleet, and the economics hinge on utilization, per-day pricing and the residual value of cars when they are sold out of the fleet. The company competes with privately held Enterprise Holdings, Hertz, Europe's Sixt, and peer-to-peer platforms like Turo and Getaround.

Full CAR guide

Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company based in Cerritos, California, focused on therapies that use the immune system to detect and attack cancer cells. Its lead candidate is IBA101, a humanized anti-CD47 monoclonal antibody intended as a next-generation immune checkpoint inhibitor, with an initial focus on advanced solid tumors including non-small cell lung cancer. The broader pipeline includes a Guanylyl Cyclase C (GCC) cancer vaccine program and, through a planned merger with InnocsAI, CAR-T and antibody candidates such as IBC101, a CD19xCD22 bivalent CAR-T cleared for an early-phase study in Korea. The company has no approved products and generates no revenue.

Full LIMN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CAR drivers: Fleet utilization and pricing recovery; Vehicle residual values and fleet mix.
• LIMN drivers: Lead anti-CD47 program; Pipeline breadth and the InnocsAI merger.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The equity is small relative to enormous fleet and corporate debt, so modest swings in used-car residual values, interest rates or demand can move the stock sharply, and the shares carry a beta well above the market. For LIMN, liminatus carries the full stack of risks that define a distressed pre-revenue biotech.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CAR if you believe its drivers more; LIMN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CAR and LIMN guides.

CAR. CAR does not screen on a simple price-to-earnings basis because trailing earnings per share are negative, so investors lean on enterprise-value-to-EBITDA and the path back toward the company's roughly $1 billion adjusted EBITDA goal. With about 35 million shares outstanding and negative book equity, the stock behaves like a leveraged call on the rental cycle. Figures are approximate and drawn from the company's 2025 full-year and first-quarter 2026 disclosures.

LIMN. For a clinical-stage biotech with no revenue, traditional metrics like P/E or price-to-sales do not apply, so the numbers that matter are cash on hand, the quarterly cash burn, and the runway between them. Here the runway is very short: a roughly $1 million quarterly loss against under $2 million in cash means the company must keep raising money to operate, which is why management disclosed going concern doubt. Read the market cap as the market's small, heavily discounted estimate of a binary pipeline rather than a multiple of any earnings, and treat each financing and clinical update as the real value driver.

Headline figures (approximate, JULY 2026): CAR shows revenue (fy2025) ~$11.7B, revenue (q1 2026) ~$2.53B, up ~4% YoY, net loss (fy2025) ~$995M, adjusted ebitda (fy2025) ~$748M; LIMN shows revenue $0 (no approved products), net loss (fy2025) ~$10.2 million, net loss (q1 2026) ~$1.1 million, cash ~$1.9 million (Mar 31, 2026).

CAR and LIMN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CAR and LIMN exposure against your real portfolio. It is not an investment adviser.